Abstract
Hypoxia is a decrease in tissue oxygen concentration, normally caused by a reduction in the partial pressure of atmospheric oxygen. Due to the exposition to hypoxia, reactive oxygen species (ROS) are continuously generated and, therefore, increased risks of oxidative lesions have been reported. ROS may severely damage lipids, proteins and DNA. The most important source of ROS during hypoxia is the mitochondria, which release cytochrome c following oxidative damage. Once released, cytochrome c may activate the caspase cascade, switching on the apoptotic pathway. ROS generation is typically associated with brain injury. The brain contains low activity of antioxidants enzymes, it is rich in lipids and it has high metabolic activity. The combination of these factors makes the brain particularly vulnerable to oxidative stress. Also, it has recently been demonstrated that ROS acts as a physiological signal in many cells, including neurons. A protective role of ROS in neuronal plasticity has been suggested. Erythropoietin (EPO), one of the best-known mediators of the physiological response to hypoxia, has been recently reported in the central nervous system. Over the last few years, EPO has been shown to exert neuroprotection, and its role as an antioxidant agent is currently under discussion. In agreement with recent works, we will present the generation of ROS during exposure to hypoxia, and we will define what degree of oxidative stress is necessary to induce physiological adaptations. Moreover, the effects of EPO will be discussed according to its newly described role as an inhibitor of the oxidative stress.
Current Chemical Biology
Title: Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?
Volume: 3 Issue: 3
Author(s): Teresa Carbonell and Ramon Rama
Affiliation:
- Department of Physiology (Biology), Avda Diagonal 645, 08028 Barcelona, Spain.,Spain
Abstract: Hypoxia is a decrease in tissue oxygen concentration, normally caused by a reduction in the partial pressure of atmospheric oxygen. Due to the exposition to hypoxia, reactive oxygen species (ROS) are continuously generated and, therefore, increased risks of oxidative lesions have been reported. ROS may severely damage lipids, proteins and DNA. The most important source of ROS during hypoxia is the mitochondria, which release cytochrome c following oxidative damage. Once released, cytochrome c may activate the caspase cascade, switching on the apoptotic pathway. ROS generation is typically associated with brain injury. The brain contains low activity of antioxidants enzymes, it is rich in lipids and it has high metabolic activity. The combination of these factors makes the brain particularly vulnerable to oxidative stress. Also, it has recently been demonstrated that ROS acts as a physiological signal in many cells, including neurons. A protective role of ROS in neuronal plasticity has been suggested. Erythropoietin (EPO), one of the best-known mediators of the physiological response to hypoxia, has been recently reported in the central nervous system. Over the last few years, EPO has been shown to exert neuroprotection, and its role as an antioxidant agent is currently under discussion. In agreement with recent works, we will present the generation of ROS during exposure to hypoxia, and we will define what degree of oxidative stress is necessary to induce physiological adaptations. Moreover, the effects of EPO will be discussed according to its newly described role as an inhibitor of the oxidative stress.
Export Options
About this article
Cite this article as:
Carbonell Teresa and Rama Ramon, Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?, Current Chemical Biology 2009; 3(3) . https://dx.doi.org/10.2174/2212796810903030238
DOI https://dx.doi.org/10.2174/2212796810903030238 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Current Neuropharmacology Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Melatonin Decreases Levels of S100β and NFκB, Increases Levels of Synaptophysinina Rat Model of Alzheimer's Disease
Current Aging Science Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Current Gene Therapy Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Magnetoencephalography in Fetuses and Neonates: A Review
Current Pediatric Reviews Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery